You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePromazine
Accession NumberDB00420  (APRD00358)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA phenothiazine with actions similar to chlorpromazine but with less antipsychotic activity. It is primarily used in short-term treatment of disturbed behavior and as an antiemetic. Promazine is not approved for use in the United States.
Structure
Thumb
Synonyms
10-(3-(Dimethylamino)propyl)phenothiazine
Frenil
N-(3-Dimethylaminopropyl)phenothiazine
N-Dimethylamino-1-methylethyl thiodiphenylamine
N,N-dimethyl-3-(10H-phenothiazin-10-yl)-propan-1-amine
Promazin
Promazina
Promazina
Promazine
Promazinum
External Identifiers
  • A 145
  • RP 3276
  • Wy 1094
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Promazine HCl Inj 50mg/mlLiquid50 mgIntramuscular; IntravenousAbbott Laboratories, Limited1981-12-312008-06-06Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
CombelenNot Available
PrazinePliva
SparineNot Available
TalofenAbbott
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Promazine Hydrochloride
53-60-1
Thumb
  • InChI Key: JIVSXRLRGOICGA-UHFFFAOYSA-N
  • Monoisotopic Mass: 320.111397079
  • Average Mass: 320.88
DBSALT000147
Categories
UNIIO9M39HTM5W
CAS number58-40-2
WeightAverage: 284.419
Monoisotopic: 284.13471934
Chemical FormulaC17H20N2S
InChI KeyZGUGWUXLJSTTMA-UHFFFAOYSA-N
InChI
InChI=1S/C17H20N2S/c1-18(2)12-7-13-19-14-8-3-5-10-16(14)20-17-11-6-4-9-15(17)19/h3-6,8-11H,7,12-13H2,1-2H3
IUPAC Name
dimethyl[3-(10H-phenothiazin-10-yl)propyl]amine
SMILES
CN(C)CCCN1C2=CC=CC=C2SC2=CC=CC=C12
Pharmacology
IndicationUsed as an adjunct for short term treatment of moderate and severe psychomotor agitation. Also used to treat agitation or restlessness in the elderly.
Structured Indications Not Available
PharmacodynamicsPromazine belongs to a group of medications known as the phenothiazine antipsychotics. It acts by blocking a variety of receptors in the brain, particularly dopamine receptors. Dopamine is involved in transmitting signals between brain cells. When there is an excess amount of dopamine in the brain it causes over-stimulation of dopamine receptors. These receptors normally act to modify behaviour and over-stimulation may result in psychotic illness. Promazine hydrochloride blocks these receptors and stops them becoming over-stimulated, thereby helping to control psychotic illness. Promazine has weak extrapyramidal and autonomic side effects which lead to its use in the elderly, for restless or psychotic patients. Its anti-psychotic effect is also weaker and it is not useful in general psychiatry.
Mechanism of actionPromazine is an antagonist at types 1, 2, and 4 dopamine receptors, 5-HT receptor types 2A and 2C, muscarinic receptors 1 through 5, alpha(1)-receptors, and histamine H1-receptors. Promazine's antipsychotic effect is due to antagonism at dopamine and serotonin type 2 receptors, with greater activity at serotonin 5-HT2 receptors than at dopamine type-2 receptors. This may explain the lack of extrapyramidal effects. Promazine does not appear to block dopamine within the tubero-infundibular tract, explaining the lower incidence of hyperprolactinemia than with typical antipsychotic agents or risperidone. Antagonism at muscarinic receptors, H1-receptors, and alpha(1)-receptors also occurs with promazine.
TargetKindPharmacological actionActionsOrganismUniProt ID
D(2) dopamine receptorProteinyes
antagonist
HumanP14416 details
5-hydroxytryptamine receptor 2AProteinunknown
antagonist
HumanP28223 details
5-hydroxytryptamine receptor 2CProteinunknown
antagonist
HumanP28335 details
D(1A) dopamine receptorProteinunknown
antagonist
HumanP21728 details
D(4) dopamine receptorProteinunknown
antagonist
HumanP21917 details
Muscarinic acetylcholine receptor M4Proteinunknown
antagonist
HumanP08173 details
Muscarinic acetylcholine receptor M2Proteinunknown
antagonist
HumanP08172 details
Muscarinic acetylcholine receptor M3Proteinunknown
antagonist
HumanP20309 details
Muscarinic acetylcholine receptor M1Proteinunknown
antagonist
HumanP11229 details
Alpha-1B adrenergic receptorProteinunknown
antagonist
HumanP35368 details
Muscarinic acetylcholine receptor M5Proteinunknown
antagonist
HumanP08912 details
Alpha-1A adrenergic receptorProteinunknown
antagonist
HumanP35348 details
Histamine H1 receptorProteinunknown
antagonist
HumanP35367 details
Alpha-1D adrenergic receptorProteinunknown
antagonist
HumanP25100 details
Related Articles
AbsorptionAbsorption may be erratic and peak plasma concentrations show large interindividual differences.
Volume of distributionNot Available
Protein binding94%
Metabolism

Hepatic, primarily to N-desmethylpromazine and promazine sulfoxide.

SubstrateEnzymesProduct
Promazine
Promazine 5-sulfoxideDetails
Promazine
N-DesmethylpromazineDetails
Promazine
Not Available
3-HydroxypromazineDetails
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicitySide effects include: extrapyramidal symptoms, drowsiness, weight gain, dry mouth, constipation, endocrine effects (such as gynaecomastia and menstrual disturbance), sensitivity to sunlight and haemolytic anaemia.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,1,1,2 TetrafluoroethaneThe risk or severity of adverse effects can be increased when Promazine is combined with 1,1,1,2 Tetrafluoroethane.Investigational
2,5-Dimethoxy-4-ethylamphetaminePromazine may decrease the stimulatory activities of 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
3,4-MethylenedioxyamphetaminePromazine may decrease the stimulatory activities of 3,4-Methylenedioxyamphetamine.Experimental, Illicit
3,4-MethylenedioxymethamphetaminePromazine may decrease the stimulatory activities of 3,4-Methylenedioxymethamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetaminePromazine may decrease the stimulatory activities of 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe metabolism of 4-Methoxyamphetamine can be decreased when combined with Promazine.Experimental, Illicit
5'-Deoxy-5'-MethylthioadenosineThe serum concentration of Promazine can be increased when it is combined with 5'-Deoxy-5'-Methylthioadenosine.Experimental
7-NitroindazoleThe risk or severity of adverse effects can be increased when Promazine is combined with 7-Nitroindazole.Experimental
AbirateroneThe serum concentration of Promazine can be increased when it is combined with Abiraterone.Approved
AcebutololPromazine may increase the hypotensive activities of Acebutolol.Approved
AcepromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Acepromazine.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Promazine is combined with Aceprometazine.Approved
AcetaminophenThe metabolism of Acetaminophen can be decreased when combined with Promazine.Approved
AcetylcholineThe metabolism of Acetylcholine can be decreased when combined with Promazine.Approved
adipiplonThe risk or severity of adverse effects can be increased when Promazine is combined with adipiplon.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Promazine is combined with Agomelatine.Approved, Investigational
AjmalineThe metabolism of Ajmaline can be decreased when combined with Promazine.Approved
AlfaxaloneThe risk or severity of adverse effects can be increased when Promazine is combined with Alfaxalone.Vet Approved
AlfentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Alfentanil.Approved, Illicit
AlfuzosinAlfuzosin may increase the QTc-prolonging activities of Promazine.Approved, Investigational
AlmotriptanThe metabolism of Almotriptan can be decreased when combined with Promazine.Approved, Investigational
AlogliptinThe metabolism of Alogliptin can be decreased when combined with Promazine.Approved
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Promazine is combined with Alphacetylmethadol.Experimental, Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Promazine.Approved, Illicit, Investigational
AlprenololThe metabolism of Alprenolol can be decreased when combined with Promazine.Approved, Withdrawn
Aluminum hydroxideAluminum hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Aluminum phosphateAluminum phosphate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
AmantadineThe therapeutic efficacy of Promazine can be decreased when used in combination with Amantadine.Approved
AminophenazoneThe metabolism of Aminophenazone can be decreased when combined with Promazine.Approved, Withdrawn
AmiodaronePromazine may increase the QTc-prolonging activities of Amiodarone.Approved, Investigational
AmisulprideThe risk or severity of adverse effects can be increased when Promazine is combined with Amisulpride.Approved, Investigational
AmitriptylineAmitriptyline may increase the QTc-prolonging activities of Promazine.Approved
AmobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Amobarbital.Approved, Illicit
AmodiaquineThe serum concentration of Promazine can be increased when it is combined with Amodiaquine.Approved
AmoxapineAmoxapine may increase the QTc-prolonging activities of Promazine.Approved
AmperozideThe risk or severity of adverse effects can be increased when Promazine is combined with Amperozide.Experimental
AmphetamineThe metabolism of Amphetamine can be decreased when combined with Promazine.Approved, Illicit
AmprenavirThe metabolism of Amprenavir can be decreased when combined with Promazine.Approved
AmsacrineThe metabolism of Amsacrine can be decreased when combined with Promazine.Approved
AnagrelidePromazine may increase the QTc-prolonging activities of Anagrelide.Approved
AntipyrineThe metabolism of Antipyrine can be decreased when combined with Promazine.Approved
Aop200704Promazine may increase the hypotensive activities of Aop200704.Investigational
ApomorphineThe therapeutic efficacy of Promazine can be decreased when used in combination with Apomorphine.Approved, Investigational
AprepitantThe serum concentration of Promazine can be increased when it is combined with Aprepitant.Approved, Investigational
AprindineThe metabolism of Aprindine can be decreased when combined with Promazine.Approved
ArformoterolArformoterol may increase the QTc-prolonging activities of Promazine.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be increased when it is combined with Promazine.Approved, Investigational
ArmodafinilThe metabolism of Promazine can be decreased when combined with Armodafinil.Approved, Investigational
ArotinololPromazine may increase the hypotensive activities of Arotinolol.Approved
Arsenic trioxidePromazine may increase the QTc-prolonging activities of Arsenic trioxide.Approved, Investigational
ArtemetherPromazine may increase the QTc-prolonging activities of Artemether.Approved
ArtemisininThe serum concentration of Promazine can be increased when it is combined with Artemisinin.Investigational
ArtesunateThe serum concentration of Promazine can be increased when it is combined with Artesunate.Approved
ArticaineThe risk or severity of adverse effects can be increased when Promazine is combined with Articaine.Approved
AsenapinePromazine may increase the QTc-prolonging activities of Asenapine.Approved
AstemizoleThe metabolism of Astemizole can be decreased when combined with Promazine.Approved, Withdrawn
AtazanavirThe metabolism of Promazine can be decreased when combined with Atazanavir.Approved, Investigational
AtenololPromazine may increase the hypotensive activities of Atenolol.Approved
AtomoxetineAtomoxetine may increase the QTc-prolonging activities of Promazine.Approved
AtovaquoneThe serum concentration of Promazine can be increased when it is combined with Atovaquone.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Azaperone.Vet Approved
AzelastinePromazine may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
AzelastineThe metabolism of Azelastine can be decreased when combined with Promazine.Approved
AzithromycinAzithromycin may increase the QTc-prolonging activities of Promazine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Promazine is combined with Baclofen.Approved
BarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Barbital.Illicit
BedaquilinePromazine may increase the QTc-prolonging activities of Bedaquiline.Approved
BefunololPromazine may increase the hypotensive activities of Befunolol.Experimental
BenperidolThe risk or severity of adverse effects can be increased when Promazine is combined with Benperidol.Investigational
BenzatropineThe metabolism of Benzatropine can be decreased when combined with Promazine.Approved
BenzocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Benzocaine.Approved
BenzphetaminePromazine may decrease the stimulatory activities of Benzphetamine.Approved, Illicit
Benzyl alcoholThe metabolism of Benzyl alcohol can be decreased when combined with Promazine.Approved
BepridilThe metabolism of Bepridil can be decreased when combined with Promazine.Approved, Withdrawn
BetaxololThe metabolism of Betaxolol can be decreased when combined with Promazine.Approved
Betulinic AcidThe serum concentration of Promazine can be increased when it is combined with Betulinic Acid.Investigational
BevantololPromazine may increase the hypotensive activities of Bevantolol.Approved
BexaroteneThe serum concentration of Promazine can be decreased when it is combined with Bexarotene.Approved, Investigational
BezitramidePromazine may increase the hypotensive activities of Bezitramide.Experimental, Illicit, Withdrawn
Bismuth SubcitrateBismuth Subcitrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
BisoprololThe metabolism of Bisoprolol can be decreased when combined with Promazine.Approved
BoceprevirThe metabolism of Promazine can be decreased when combined with Boceprevir.Approved
BopindololPromazine may increase the hypotensive activities of Bopindolol.Approved
BortezomibBortezomib may increase the QTc-prolonging activities of Promazine.Approved, Investigational
BosentanThe serum concentration of Promazine can be decreased when it is combined with Bosentan.Approved, Investigational
BrexpiprazoleThe serum concentration of Brexpiprazole can be increased when it is combined with Promazine.Approved
BrimonidineThe risk or severity of adverse effects can be increased when Promazine is combined with Brimonidine.Approved
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
BromazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Bromazepam.Approved, Illicit
BromocriptineThe therapeutic efficacy of Promazine can be decreased when used in combination with Bromocriptine.Approved, Investigational
BrompheniramineThe metabolism of Brompheniramine can be decreased when combined with Promazine.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Promazine is combined with Brotizolam.Approved, Withdrawn
BucindololPromazine may increase the hypotensive activities of Bucindolol.Investigational
BufuralolThe metabolism of Bufuralol can be decreased when combined with Promazine.Experimental, Investigational
BupivacaineThe metabolism of Bupivacaine can be decreased when combined with Promazine.Approved, Investigational
BupranololPromazine may increase the hypotensive activities of Bupranolol.Approved
BuprenorphinePromazine may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe metabolism of Bupropion can be decreased when combined with Promazine.Approved
BuserelinBuserelin may increase the QTc-prolonging activities of Promazine.Approved
BuspironeThe metabolism of Buspirone can be decreased when combined with Promazine.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Promazine.Approved, Illicit
ButacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Butacaine.Vet Approved
ButalbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Butalbital.Approved, Illicit
ButambenThe risk or severity of adverse effects can be increased when Promazine is combined with Butamben.Approved
ButethalThe risk or severity of adverse effects can be increased when Promazine is combined with Butethal.Approved, Illicit
ButorphanolThe risk or severity of adverse effects can be increased when Promazine is combined with Butorphanol.Approved, Illicit, Vet Approved
CabergolineThe risk or severity of adverse effects can be increased when Cabergoline is combined with Promazine.Approved
CaffeineThe metabolism of Promazine can be decreased when combined with Caffeine.Approved
Calcium carbonateCalcium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
CapecitabineThe metabolism of Promazine can be decreased when combined with Capecitabine.Approved, Investigational
CaptoprilThe metabolism of Captopril can be decreased when combined with Promazine.Approved
CarbamazepineThe metabolism of Promazine can be increased when combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Promazine is combined with Carbinoxamine.Approved
CarfentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Carfentanil.Illicit, Vet Approved
CariprazineThe metabolism of Cariprazine can be decreased when combined with Promazine.Approved
CarisoprodolThe risk or severity of adverse effects can be increased when Promazine is combined with Carisoprodol.Approved
CarteololThe metabolism of Carteolol can be decreased when combined with Promazine.Approved
CarvedilolThe metabolism of Carvedilol can be decreased when combined with Promazine.Approved, Investigational
CeliprololPromazine may increase the hypotensive activities of Celiprolol.Approved, Investigational
CephalexinThe metabolism of Cephalexin can be decreased when combined with Promazine.Approved, Vet Approved
CeritinibThe serum concentration of Promazine can be increased when it is combined with Ceritinib.Approved
CetirizineThe risk or severity of adverse effects can be increased when Promazine is combined with Cetirizine.Approved
CevimelineThe metabolism of Cevimeline can be decreased when combined with Promazine.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Promazine is combined with Chloral hydrate.Approved, Illicit, Vet Approved
ChloramphenicolThe metabolism of Promazine can be decreased when combined with Chloramphenicol.Approved, Vet Approved
ChlordiazepoxideThe metabolism of Chlordiazepoxide can be decreased when combined with Promazine.Approved, Illicit
ChlormezanoneThe risk or severity of adverse effects can be increased when Promazine is combined with Chlormezanone.Approved, Withdrawn
ChloroprocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Chloroprocaine.Approved
ChloroquinePromazine may increase the QTc-prolonging activities of Chloroquine.Approved, Vet Approved
ChlorphenamineThe metabolism of Chlorphenamine can be decreased when combined with Promazine.Approved
ChlorphenterminePromazine may decrease the stimulatory activities of Chlorphentermine.Illicit, Withdrawn
ChlorpromazinePromazine may increase the QTc-prolonging activities of Chlorpromazine.Approved, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Promazine is combined with Chlorprothixene.Approved, Withdrawn
ChlorzoxazoneThe metabolism of Chlorzoxazone can be decreased when combined with Promazine.Approved
CholecalciferolThe metabolism of Promazine can be decreased when combined with Cholecalciferol.Approved, Nutraceutical
CilostazolThe metabolism of Cilostazol can be decreased when combined with Promazine.Approved
CimetidineThe metabolism of Promazine can be decreased when combined with Cimetidine.Approved
CinchocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Cinchocaine.Approved, Vet Approved
CinnarizineThe metabolism of Cinnarizine can be decreased when combined with Promazine.Approved
CiprofloxacinPromazine may increase the QTc-prolonging activities of Ciprofloxacin.Approved, Investigational
CisapridePromazine may increase the QTc-prolonging activities of Cisapride.Approved, Investigational, Withdrawn
CitalopramPromazine may increase the QTc-prolonging activities of Citalopram.Approved
ClarithromycinPromazine may increase the QTc-prolonging activities of Clarithromycin.Approved
ClemastineThe metabolism of Promazine can be decreased when combined with Clemastine.Approved
ClevidipineThe metabolism of Clevidipine can be decreased when combined with Promazine.Approved
ClidiniumThe risk or severity of adverse effects can be increased when Promazine is combined with Clidinium.Approved
ClobazamThe risk or severity of adverse effects can be increased when Promazine is combined with Clobazam.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when Promazine is combined with clomethiazole.Investigational
ClomipramineClomipramine may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
ClonazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Clonazepam.Approved, Illicit
ClonidineThe metabolism of Clonidine can be decreased when combined with Promazine.Approved
ClorazepateThe risk or severity of adverse effects can be increased when Promazine is combined with Clorazepate.Approved, Illicit
ClotrimazoleThe metabolism of Promazine can be decreased when combined with Clotrimazole.Approved, Vet Approved
ClozapineClozapine may increase the QTc-prolonging activities of Promazine.Approved
CobicistatThe metabolism of Promazine can be decreased when combined with Cobicistat.Approved
CocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Cocaine.Approved, Illicit
CodeineThe therapeutic efficacy of Codeine can be decreased when used in combination with Promazine.Approved, Illicit
ConivaptanThe serum concentration of Promazine can be increased when it is combined with Conivaptan.Approved, Investigational
CrizotinibPromazine may increase the QTc-prolonging activities of Crizotinib.Approved
CyclizineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyclizine.Approved
CyclobenzaprineThe metabolism of Cyclobenzaprine can be decreased when combined with Promazine.Approved
CyclophosphamideThe metabolism of Cyclophosphamide can be decreased when combined with Promazine.Approved, Investigational
CyclosporineThe metabolism of Promazine can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Promazine is combined with Cyproheptadine.Approved
Cyproterone acetateThe serum concentration of Promazine can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
DabrafenibThe serum concentration of Promazine can be decreased when it is combined with Dabrafenib.Approved
DantroleneThe risk or severity of adverse effects can be increased when Promazine is combined with Dantrolene.Approved
DapagliflozinThe metabolism of Dapagliflozin can be decreased when combined with Promazine.Approved
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Promazine.Approved
DapoxetineThe risk or severity of adverse effects can be increased when Promazine is combined with Dapoxetine.Investigational
DapsoneThe serum concentration of Promazine can be increased when it is combined with Dapsone.Approved, Investigational
DarifenacinThe metabolism of Darifenacin can be decreased when combined with Promazine.Approved, Investigational
DarunavirThe metabolism of Promazine can be decreased when combined with Darunavir.Approved
DasabuvirThe metabolism of Dasabuvir can be decreased when combined with Promazine.Approved
DasatinibThe serum concentration of Promazine can be increased when it is combined with Dasatinib.Approved, Investigational
DebrisoquinThe metabolism of Debrisoquin can be decreased when combined with Promazine.Approved
DeferasiroxThe serum concentration of Promazine can be decreased when it is combined with Deferasirox.Approved, Investigational
DegarelixDegarelix may increase the QTc-prolonging activities of Promazine.Approved
DelavirdineThe metabolism of Promazine can be decreased when combined with Delavirdine.Approved
deramciclaneThe risk or severity of adverse effects can be increased when Promazine is combined with deramciclane.Investigational
DesfluraneDesflurane may increase the QTc-prolonging activities of Promazine.Approved
DesipramineDesipramine may increase the QTc-prolonging activities of Promazine.Approved
DesloratadineThe risk or severity of adverse effects can be increased when Promazine is combined with Desloratadine.Approved, Investigational
DesvenlafaxineThe risk or severity of adverse effects can be increased when Desvenlafaxine is combined with Promazine.Approved
DetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Detomidine.Vet Approved
DexamethasoneThe serum concentration of Promazine can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexbrompheniramine.Approved
DexfenfluramineThe metabolism of Dexfenfluramine can be decreased when combined with Promazine.Approved, Illicit, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Dexmedetomidine.Approved, Vet Approved
DexmethylphenidateThe metabolism of Dexmethylphenidate can be decreased when combined with Promazine.Approved
DextroamphetamineThe metabolism of Dextroamphetamine can be decreased when combined with Promazine.Approved, Illicit
DextromethorphanThe metabolism of Dextromethorphan can be decreased when combined with Promazine.Approved
DextromoramideThe risk or severity of adverse effects can be increased when Promazine is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of adverse effects can be increased when Promazine is combined with Dextropropoxyphene.Approved, Illicit, Withdrawn
DezocineThe risk or severity of adverse effects can be increased when Promazine is combined with Dezocine.Approved
DiazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Diazepam.Approved, Illicit, Vet Approved
DiethylpropionPromazine may decrease the stimulatory activities of Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Promazine is combined with Difenoxin.Approved, Illicit
DihydroartemisininThe serum concentration of Promazine can be increased when it is combined with Dihydroartemisinin.Approved
DihydrocodeineThe metabolism of Dihydrocodeine can be decreased when combined with Promazine.Approved, Illicit
DihydroergotamineThe metabolism of Promazine can be decreased when combined with Dihydroergotamine.Approved
DihydroetorphineThe risk or severity of adverse effects can be increased when Promazine is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of adverse effects can be increased when Promazine is combined with Dihydromorphine.Experimental, Illicit
DiltiazemThe metabolism of Promazine can be decreased when combined with Diltiazem.Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Promazine is combined with Dimenhydrinate.Approved
DiphenhydramineDiphenhydramine may increase the QTc-prolonging activities of Promazine.Approved
DiphenoxylateThe risk or severity of adverse effects can be increased when Promazine is combined with Diphenoxylate.Approved, Illicit
DisopyramidePromazine may increase the QTc-prolonging activities of Disopyramide.Approved
DofetilidePromazine may increase the QTc-prolonging activities of Dofetilide.Approved
DolasetronPromazine may increase the QTc-prolonging activities of Dolasetron.Approved
DomperidonePromazine may increase the QTc-prolonging activities of Domperidone.Approved, Investigational, Vet Approved
DonepezilThe metabolism of Donepezil can be decreased when combined with Promazine.Approved
DopamineThe metabolism of Dopamine can be decreased when combined with Promazine.Approved
DoramectinThe risk or severity of adverse effects can be increased when Promazine is combined with Doramectin.Vet Approved
DoxazosinThe metabolism of Doxazosin can be decreased when combined with Promazine.Approved
DoxepinDoxepin may increase the QTc-prolonging activities of Promazine.Approved
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Promazine.Approved, Investigational
DoxorubicinThe metabolism of Doxorubicin can be decreased when combined with Promazine.Approved, Investigational
DoxycyclineThe serum concentration of Promazine can be increased when it is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
DPDPEThe risk or severity of adverse effects can be increased when Promazine is combined with DPDPE.Investigational
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Illicit
DronedaronePromazine may increase the QTc-prolonging activities of Dronedarone.Approved
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Promazine is combined with Drotebanol.Experimental, Illicit
DuloxetineThe metabolism of Duloxetine can be decreased when combined with Promazine.Approved
DyclonineThe risk or severity of adverse effects can be increased when Promazine is combined with Dyclonine.Approved
EcgonineThe risk or severity of adverse effects can be increased when Promazine is combined with Ecgonine.Experimental, Illicit
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when Promazine is combined with ECGONINE METHYL ESTER.Experimental
EcopipamThe risk or severity of adverse effects can be increased when Promazine is combined with Ecopipam.Investigational
EfavirenzThe serum concentration of Promazine can be decreased when it is combined with Efavirenz.Approved, Investigational
EletriptanThe metabolism of Eletriptan can be decreased when combined with Promazine.Approved, Investigational
EliglustatThe serum concentration of Eliglustat can be increased when it is combined with Promazine.Approved
EncainideThe metabolism of Encainide can be decreased when combined with Promazine.Approved, Withdrawn
EnclomipheneThe metabolism of Enclomiphene can be decreased when combined with Promazine.Investigational
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Promazine.Approved, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Promazine is combined with Entacapone.Approved, Investigational
EnzalutamideThe serum concentration of Promazine can be decreased when it is combined with Enzalutamide.Approved
EpinastineThe metabolism of Epinastine can be decreased when combined with Promazine.Approved, Investigational
Ergoloid mesylateThe risk or severity of adverse effects can be increased when Ergoloid mesylate is combined with Promazine.Approved
ErgonovineThe risk or severity of adverse effects can be increased when Ergonovine is combined with Promazine.Approved
ErgotamineThe risk or severity of adverse effects can be increased when Ergotamine is combined with Promazine.Approved
EribulinEribulin may increase the QTc-prolonging activities of Promazine.Approved, Investigational
ErlotinibThe metabolism of Erlotinib can be decreased when combined with Promazine.Approved, Investigational
ErythromycinErythromycin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
EscitalopramPromazine may increase the QTc-prolonging activities of Escitalopram.Approved, Investigational
Eslicarbazepine acetateThe serum concentration of Promazine can be decreased when it is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe metabolism of Esmirtazapine can be decreased when combined with Promazine.Investigational
EsmololPromazine may increase the hypotensive activities of Esmolol.Approved
EsomeprazoleThe metabolism of Promazine can be decreased when combined with Esomeprazole.Approved, Investigational
EstazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Estazolam.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Promazine.Approved
EthanolPromazine may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Promazine.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Promazine is combined with Ethosuximide.Approved
EthotoinThe risk or severity of adverse effects can be increased when Promazine is combined with Ethotoin.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl carbamate.Withdrawn
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Promazine is combined with Ethyl loflazepate.Approved, Illicit
EthylmorphineThe metabolism of Ethylmorphine can be decreased when combined with Promazine.Approved, Illicit
EtidocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Etidocaine.Approved
EtifoxineThe risk or severity of adverse effects can be increased when Promazine is combined with Etifoxine.Withdrawn
EtizolamThe risk or severity of adverse effects can be increased when Promazine is combined with Etizolam.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Promazine.Approved
EtoperidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Etoperidone.Approved
EtoricoxibThe metabolism of Etoricoxib can be decreased when combined with Promazine.Approved, Investigational
EtorphineThe risk or severity of adverse effects can be increased when Promazine is combined with Etorphine.Illicit, Vet Approved
EtravirineThe serum concentration of Promazine can be decreased when it is combined with Etravirine.Approved
EzogabineEzogabine may increase the QTc-prolonging activities of Promazine.Approved
FamotidineFamotidine may increase the QTc-prolonging activities of Promazine.Approved
FelbamateFelbamate may increase the QTc-prolonging activities of Promazine.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Promazine is combined with Fencamfamine.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of adverse effects can be increased when Promazine is combined with Fenfluramine.Illicit, Withdrawn
FentanylThe risk or severity of adverse effects can be increased when Promazine is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FesoterodineThe metabolism of Fesoterodine can be decreased when combined with Promazine.Approved
FexofenadineThe risk or severity of adverse effects can be increased when Promazine is combined with Fexofenadine.Approved
FingolimodFingolimod may increase the QTc-prolonging activities of Promazine.Approved, Investigational
FlecainidePromazine may increase the QTc-prolonging activities of Flecainide.Approved, Withdrawn
FlibanserinThe risk or severity of adverse effects can be increased when Promazine is combined with Flibanserin.Approved
FloxuridineThe metabolism of Promazine can be decreased when combined with Floxuridine.Approved
FluconazoleThe metabolism of Promazine can be decreased when combined with Fluconazole.Approved
FludiazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Fludiazepam.Approved, Illicit
FlunarizineThe metabolism of Flunarizine can be decreased when combined with Promazine.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Flunitrazepam.Approved, Illicit
FluorouracilThe metabolism of Promazine can be decreased when combined with Fluorouracil.Approved
FluoxetinePromazine may increase the QTc-prolonging activities of Fluoxetine.Approved, Vet Approved
FlupentixolPromazine may increase the QTc-prolonging activities of Flupentixol.Approved, Withdrawn
FluphenazineThe metabolism of Fluphenazine can be decreased when combined with Promazine.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Flurazepam.Approved, Illicit
FluspirileneThe risk or severity of adverse effects can be increased when Promazine is combined with Fluspirilene.Approved
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Promazine is combined with Fluticasone Propionate.Approved
FluvastatinThe metabolism of Fluvastatin can be decreased when combined with Promazine.Approved
FluvoxamineThe metabolism of Promazine can be decreased when combined with Fluvoxamine.Approved, Investigational
FormoterolFormoterol may increase the QTc-prolonging activities of Promazine.Approved, Investigational
FosamprenavirThe metabolism of Promazine can be decreased when combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Promazine can be increased when it is combined with Fosaprepitant.Approved
FoscarnetFoscarnet may increase the QTc-prolonging activities of Promazine.Approved
FosphenytoinThe metabolism of Promazine can be increased when combined with Fosphenytoin.Approved
FospropofolThe risk or severity of adverse effects can be increased when Promazine is combined with Fospropofol.Approved, Illicit
FrovatriptanThe risk or severity of adverse effects can be increased when Frovatriptan is combined with Promazine.Approved, Investigational
Fusidic AcidThe serum concentration of Promazine can be increased when it is combined with Fusidic Acid.Approved
GabapentinThe risk or severity of adverse effects can be increased when Promazine is combined with Gabapentin.Approved, Investigational
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Promazine is combined with gabapentin enacarbil.Approved
Gadobenic acidPromazine may increase the QTc-prolonging activities of Gadobenic acid.Approved
GalantamineGalantamine may increase the QTc-prolonging activities of Promazine.Approved
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Promazine is combined with Gamma Hydroxybutyric Acid.Approved, Illicit
GefitinibThe metabolism of Gefitinib can be decreased when combined with Promazine.Approved, Investigational
GemfibrozilThe metabolism of Promazine can be decreased when combined with Gemfibrozil.Approved
GemifloxacinPromazine may increase the QTc-prolonging activities of Gemifloxacin.Approved, Investigational
GepironeThe risk or severity of adverse effects can be increased when Promazine is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Promazine is combined with Glutethimide.Approved, Illicit
GoserelinGoserelin may increase the QTc-prolonging activities of Promazine.Approved
GranisetronPromazine may increase the QTc-prolonging activities of Granisetron.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Promazine is combined with Guanfacine.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Halazepam.Approved, Illicit, Withdrawn
HalofantrineThe serum concentration of Promazine can be increased when it is combined with Halofantrine.Approved
HaloperidolPromazine may increase the QTc-prolonging activities of Haloperidol.Approved
HalothaneThe metabolism of Halothane can be decreased when combined with Promazine.Approved, Vet Approved
HeroinThe risk or severity of adverse effects can be increased when Promazine is combined with Heroin.Approved, Illicit
HexobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Hexobarbital.Approved
HistrelinHistrelin may increase the QTc-prolonging activities of Promazine.Approved
HydrocodonePromazine may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit
HydromorphoneThe metabolism of Hydromorphone can be decreased when combined with Promazine.Approved, Illicit
Hydroxyamphetamine hydrobromidePromazine may decrease the stimulatory activities of Hydroxyamphetamine hydrobromide.Approved
HydroxychloroquineThe serum concentration of Promazine can be increased when it is combined with Hydroxychloroquine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
IbandronateIbandronate may increase the QTc-prolonging activities of Promazine.Approved, Investigational
IbrutinibThe metabolism of Ibrutinib can be decreased when combined with Promazine.Approved
IbutilidePromazine may increase the QTc-prolonging activities of Ibutilide.Approved
IdarubicinThe metabolism of Idarubicin can be decreased when combined with Promazine.Approved
IdelalisibThe serum concentration of Promazine can be increased when it is combined with Idelalisib.Approved
IloperidonePromazine may increase the QTc-prolonging activities of Iloperidone.Approved
ImatinibThe metabolism of Promazine can be decreased when combined with Imatinib.Approved
ImipramineImipramine may increase the QTc-prolonging activities of Promazine.Approved
IndacaterolIndacaterol may increase the QTc-prolonging activities of Promazine.Approved
IndalpineThe risk or severity of adverse effects can be increased when Promazine is combined with Indalpine.Investigational, Withdrawn
IndapamideIndapamide may increase the QTc-prolonging activities of Promazine.Approved
IndenololPromazine may increase the hypotensive activities of Indenolol.Withdrawn
IndinavirThe metabolism of Promazine can be decreased when combined with Indinavir.Approved
Ipratropium bromideThe metabolism of Ipratropium bromide can be decreased when combined with Promazine.Approved
IrbesartanThe metabolism of Promazine can be decreased when combined with Irbesartan.Approved, Investigational
IsavuconazoniumThe metabolism of Promazine can be decreased when combined with Isavuconazonium.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Isocarboxazid is combined with Promazine.Approved
IsofluraneIsoflurane may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
IsoniazidThe metabolism of Promazine can be decreased when combined with Isoniazid.Approved
IsradipineIsradipine may increase the QTc-prolonging activities of Promazine.Approved
ItraconazoleThe metabolism of Promazine can be decreased when combined with Itraconazole.Approved, Investigational
IvabradineIvabradine may increase the QTc-prolonging activities of Promazine.Approved
IvacaftorThe serum concentration of Promazine can be increased when it is combined with Ivacaftor.Approved
IxazomibThe metabolism of Ixazomib can be decreased when combined with Promazine.Approved
KetamineThe risk or severity of adverse effects can be increased when Promazine is combined with Ketamine.Approved, Vet Approved
KetazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Ketazolam.Approved
KetobemidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Ketobemidone.Approved
KetoconazoleThe metabolism of Promazine can be decreased when combined with Ketoconazole.Approved, Investigational
LabetalolThe metabolism of Labetalol can be decreased when combined with Promazine.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Promazine is combined with Lamotrigine.Approved, Investigational
LapatinibLapatinib may increase the QTc-prolonging activities of Promazine.Approved, Investigational
LeflunomideThe metabolism of Promazine can be decreased when combined with Leflunomide.Approved, Investigational
LenvatinibPromazine may increase the QTc-prolonging activities of Lenvatinib.Approved
LeuprolideLeuprolide may increase the QTc-prolonging activities of Promazine.Approved, Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Promazine is combined with Levetiracetam.Approved, Investigational
LevobunololPromazine may increase the hypotensive activities of Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Levobupivacaine.Approved
LevocabastineThe risk or severity of adverse effects can be increased when Promazine is combined with Levocabastine.Approved
LevocetirizineThe risk or severity of adverse effects can be increased when Promazine is combined with Levocetirizine.Approved
LevodopaThe therapeutic efficacy of Promazine can be decreased when used in combination with Levodopa.Approved
LevofloxacinPromazine may increase the QTc-prolonging activities of Levofloxacin.Approved, Investigational
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Promazine is combined with Levomethadyl Acetate.Approved
LevomilnacipranThe metabolism of Levomilnacipran can be decreased when combined with Promazine.Approved
LevorphanolThe risk or severity of adverse effects can be increased when Promazine is combined with Levorphanol.Approved
LidocaineThe metabolism of Promazine can be decreased when combined with Lidocaine.Approved, Vet Approved
LinezolidThe risk or severity of adverse effects can be increased when Linezolid is combined with Promazine.Approved, Investigational
LisdexamfetaminePromazine may decrease the stimulatory activities of Lisdexamfetamine.Approved, Investigational
LisurideThe metabolism of Lisuride can be decreased when combined with Promazine.Approved
LithiumLithium may increase the neurotoxic activities of Promazine.Approved
LofentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Lofentanil.Illicit
LomustineThe metabolism of Lomustine can be decreased when combined with Promazine.Approved
LoperamideThe metabolism of Loperamide can be decreased when combined with Promazine.Approved
LopinavirPromazine may increase the QTc-prolonging activities of Lopinavir.Approved
LoratadineThe metabolism of Loratadine can be decreased when combined with Promazine.Approved
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Promazine.Approved
LorcaserinThe metabolism of Lorcaserin can be decreased when combined with Promazine.Approved
LosartanThe metabolism of Promazine can be decreased when combined with Losartan.Approved
LovastatinThe metabolism of Promazine can be decreased when combined with Lovastatin.Approved, Investigational
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Promazine.Approved
Lu AA21004The risk or severity of adverse effects can be increased when Promazine is combined with Lu AA21004.Investigational
LuliconazoleThe serum concentration of Promazine can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Promazine can be decreased when it is combined with Lumacaftor.Approved
LumefantrinePromazine may increase the QTc-prolonging activities of Lumefantrine.Approved
LurasidoneThe risk or severity of adverse effects can be increased when Promazine is combined with Lurasidone.Approved
MagaldrateMagaldrate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Withdrawn
Magnesium carbonateMagnesium carbonate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium hydroxideMagnesium hydroxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium oxideMagnesium oxide can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Vet Approved
Magnesium TrisilicateMagnesium Trisilicate can cause a decrease in the absorption of Promazine resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
MaprotilineMaprotiline may increase the QTc-prolonging activities of Promazine.Approved
MeclizineThe risk or severity of adverse effects can be increased when Promazine is combined with Meclizine.Approved
MedetomidineThe risk or severity of adverse effects can be increased when Promazine is combined with Medetomidine.Vet Approved
MefloquineThe serum concentration of Promazine can be increased when it is combined with Mefloquine.Approved
MelatoninThe risk or severity of adverse effects can be increased when Promazine is combined with Melatonin.Approved, Nutraceutical, Vet Approved
MelperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Melperone.Approved
MephedronePromazine may decrease the stimulatory activities of Mephedrone.Investigational
MephenterminePromazine may decrease the stimulatory activities of Mephentermine.Approved
MephenytoinThe metabolism of Mephenytoin can be decreased when combined with Promazine.Investigational, Withdrawn
MepivacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Mepivacaine.Approved, Vet Approved
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Promazine.Approved, Illicit
MequitazinePromazine may increase the arrhythmogenic activities of Mequitazine.Approved
MesoridazineThe metabolism of Mesoridazine can be decreased when combined with Promazine.Approved
MetaxaloneThe risk or severity of adverse effects can be increased when Promazine is combined with Metaxalone.Approved
MethadoneMethadone may increase the QTc-prolonging activities of Promazine.Approved
Methadyl AcetateThe risk or severity of adverse effects can be increased when Promazine is combined with Methadyl Acetate.Approved, Illicit
MethamphetamineThe metabolism of Methamphetamine can be decreased when combined with Promazine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Promazine is combined with Methapyrilene.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Promazine is combined with Methaqualone.Illicit, Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Promazine is combined with Methocarbamol.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Promazine is combined with Methohexital.Approved
MethotrimeprazinePromazine may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved
MethoxyfluraneThe metabolism of Methoxyflurane can be decreased when combined with Promazine.Approved, Vet Approved
MethsuximideThe risk or severity of adverse effects can be increased when Promazine is combined with Methsuximide.Approved
MethylphenidateThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Promazine is combined with Methylphenobarbital.Approved
MethyprylonThe metabolism of Methyprylon can be decreased when combined with Promazine.Approved, Illicit, Withdrawn
MetipranololPromazine may increase the hypotensive activities of Metipranolol.Approved
MetoclopramideThe risk or severity of adverse effects can be increased when Metoclopramide is combined with Promazine.Approved, Investigational
MetoprololThe metabolism of Metoprolol can be decreased when combined with Promazine.Approved, Investigational
MetronidazoleMetronidazole may increase the QTc-prolonging activities of Promazine.Approved
MetyrosinePromazine may increase the sedative activities of Metyrosine.Approved
MexiletineThe metabolism of Promazine can be decreased when combined with Mexiletine.Approved
MianserinThe metabolism of Mianserin can be decreased when combined with Promazine.Approved
MidazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Midazolam.Approved, Illicit
MifepristoneMifepristone may increase the QTc-prolonging activities of Promazine.Approved, Investigational
MilnacipranThe risk or severity of adverse effects can be increased when Promazine is combined with Milnacipran.Approved
MinaprineThe metabolism of Minaprine can be decreased when combined with Promazine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Investigational
MirabegronMirabegron may increase the QTc-prolonging activities of Promazine.Approved
MirtazapinePromazine may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.Approved
MitotaneThe serum concentration of Promazine can be decreased when it is combined with Mitotane.Approved
MizoribineThe serum concentration of Promazine can be increased when it is combined with Mizoribine.Investigational
MMDAPromazine may decrease the stimulatory activities of MMDA.Experimental, Illicit
MoclobemideThe metabolism of Moclobemide can be decreased when combined with Promazine.Approved
ModafinilThe serum concentration of Promazine can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilMoexipril may increase the QTc-prolonging activities of Promazine.Approved
MolindoneThe risk or severity of adverse effects can be increased when Promazine is combined with Molindone.Approved
MorphineThe metabolism of Morphine can be decreased when combined with Promazine.Approved, Investigational
MoxifloxacinMoxifloxacin may increase the QTc-prolonging activities of Promazine.Approved, Investigational
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved, Investigational
NadololPromazine may increase the hypotensive activities of Nadolol.Approved
NafcillinThe serum concentration of Promazine can be decreased when it is combined with Nafcillin.Approved
NalbuphineThe risk or severity of adverse effects can be increased when Promazine is combined with Nalbuphine.Approved
NaratriptanThe risk or severity of adverse effects can be increased when Naratriptan is combined with Promazine.Approved, Investigational
NateglinideThe metabolism of Nateglinide can be decreased when combined with Promazine.Approved, Investigational
NebivololThe serum concentration of Nebivolol can be increased when it is combined with Promazine.Approved, Investigational
NefazodoneThe metabolism of Promazine can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Promazine can be decreased when combined with Nelfinavir.Approved
NetupitantThe serum concentration of Promazine can be increased when it is combined with Netupitant.Approved
NevirapineThe metabolism of Promazine can be increased when combined with Nevirapine.Approved
NicardipineThe metabolism of Promazine can be decreased when combined with Nicardipine.Approved
NicergolineThe metabolism of Nicergoline can be decreased when combined with Promazine.Approved
NicotineThe metabolism of Nicotine can be decreased when combined with Promazine.Approved
NifedipineThe metabolism of Nifedipine can be decreased when combined with Promazine.Approved
NilotinibPromazine may increase the QTc-prolonging activities of Nilotinib.Approved, Investigational
NitrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrazepam.Approved
NitrofuralThe metabolism of Nitrofural can be decreased when combined with Promazine.Approved, Vet Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Promazine is combined with Nitrous oxide.Approved, Vet Approved
NorfloxacinNorfloxacin may increase the QTc-prolonging activities of Promazine.Approved
NormethadoneThe risk or severity of adverse effects can be increased when Promazine is combined with Normethadone.Approved, Illicit
NortriptylineNortriptyline may increase the QTc-prolonging activities of Promazine.Approved
OctreotideOctreotide may increase the QTc-prolonging activities of Promazine.Approved, Investigational
OfloxacinPromazine may increase the QTc-prolonging activities of Ofloxacin.Approved
OlanzapineOlanzapine may increase the QTc-prolonging activities of Promazine.Approved, Investigational
OlaparibThe metabolism of Promazine can be decreased when combined with Olaparib.Approved
OlodaterolOlodaterol may increase the QTc-prolonging activities of Promazine.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Promazine is combined with Olopatadine.Approved
OmeprazoleThe metabolism of Promazine can be decreased when combined with Omeprazole.Approved, Investigational, Vet Approved
OndansetronPromazine may increase the QTc-prolonging activities of Ondansetron.Approved
OpiumThe risk or severity of adverse effects can be increased when Promazine is combined with Opium.Approved, Illicit
OrphenadrinePromazine may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OsanetantThe risk or severity of adverse effects can be increased when Promazine is combined with Osanetant.Investigational
OsimertinibThe serum concentration of Promazine can be increased when it is combined with Osimertinib.Approved
OxazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Oxazepam.Approved
OxetacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxetacaine.Investigational
OxprenololThe risk or severity of adverse effects can be increased when Promazine is combined with Oxprenolol.Approved
OxybuprocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Oxybuprocaine.Approved
OxycodoneThe metabolism of Oxycodone can be decreased when combined with Promazine.Approved, Illicit, Investigational
OxymorphoneThe metabolism of Oxymorphone can be decreased when combined with Promazine.Approved, Investigational, Vet Approved
OxytocinOxytocin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
PalbociclibThe serum concentration of Promazine can be increased when it is combined with Palbociclib.Approved
PaliperidonePromazine may increase the QTc-prolonging activities of Paliperidone.Approved
PalonosetronThe metabolism of Palonosetron can be decreased when combined with Promazine.Approved, Investigational
PanobinostatPromazine may increase the QTc-prolonging activities of Panobinostat.Approved, Investigational
PantoprazoleThe metabolism of Promazine can be decreased when combined with Pantoprazole.Approved
ParaldehydePromazine may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved
ParoxetineParoxetine may increase the QTc-prolonging activities of Promazine.Approved, Investigational
PasireotidePasireotide may increase the QTc-prolonging activities of Promazine.Approved
PazopanibPromazine may increase the QTc-prolonging activities of Pazopanib.Approved
Peginterferon alfa-2bThe serum concentration of Promazine can be increased when it is combined with Peginterferon alfa-2b.Approved
PenbutololPromazine may increase the hypotensive activities of Penbutolol.Approved, Investigational
PentamidinePromazine may increase the QTc-prolonging activities of Pentamidine.Approved
PentazocineThe risk or severity of adverse effects can be increased when Promazine is combined with Pentazocine.Approved, Vet Approved
PentobarbitalThe metabolism of Promazine can be increased when combined with Pentobarbital.Approved, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
PerazineThe risk or severity of adverse effects can be increased when Promazine is combined with Perazine.Investigational
PerflutrenPromazine may increase the QTc-prolonging activities of Perflutren.Approved
PerhexilineThe metabolism of Perhexiline can be decreased when combined with Promazine.Approved
PerospironeThe risk or severity of adverse effects can be increased when Promazine is combined with Perospirone.Approved
PerphenazineThe metabolism of Perphenazine can be decreased when combined with Promazine.Approved
PethidineThe metabolism of Pethidine can be decreased when combined with Promazine.Approved
PhenacetinThe metabolism of Phenacetin can be decreased when combined with Promazine.Withdrawn
PhenelzineThe risk or severity of adverse effects can be increased when Phenelzine is combined with Promazine.Approved
PhenforminThe metabolism of Phenformin can be decreased when combined with Promazine.Approved, Withdrawn
PhenobarbitalThe metabolism of Promazine can be increased when combined with Phenobarbital.Approved
PhenoxyethanolThe risk or severity of adverse effects can be increased when Promazine is combined with Phenoxyethanol.Approved
PhenterminePromazine may decrease the stimulatory activities of Phentermine.Approved, Illicit
PhenytoinThe metabolism of Promazine can be increased when combined with Phenytoin.Approved, Vet Approved
PimozidePromazine may increase the QTc-prolonging activities of Pimozide.Approved
PindololThe metabolism of Pindolol can be decreased when combined with Promazine.Approved
PipamperoneThe risk or severity of adverse effects can be increased when Promazine is combined with Pipamperone.Approved
PiperazineThe metabolism of Piperazine can be decreased when combined with Promazine.Approved, Vet Approved
PipotiazineThe metabolism of Pipotiazine can be decreased when combined with Promazine.Approved
PiribedilThe therapeutic efficacy of Promazine can be decreased when used in combination with Piribedil.Investigational
PiritramideThe risk or severity of adverse effects can be increased when Promazine is combined with Piritramide.Investigational
PizotifenThe risk or severity of adverse effects can be increased when Promazine is combined with Pizotifen.Approved
PomalidomideThe risk or severity of adverse effects can be increased when Promazine is combined with Pomalidomide.Approved
PonatinibThe metabolism of Ponatinib can be decreased when combined with Promazine.Approved
PosaconazoleThe metabolism of Promazine can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PractololPromazine may increase the hypotensive activities of Practolol.Approved
PramipexolePromazine may increase the sedative activities of Pramipexole.Approved, Investigational
PramocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Pramocaine.Approved
PrazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Prazepam.Approved, Illicit
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Promazine.Approved, Illicit, Investigational
PregnanoloneThe risk or severity of adverse effects can be increased when Promazine is combined with Pregnanolone.Investigational
PrilocaineThe risk or severity of adverse effects can be increased when Promazine is combined with Prilocaine.Approved
PrimaquinePromazine may increase the QTc-prolonging activities of Primaquine.Approved
PrimidoneThe metabolism of Promazine can be increased when combined with Primidone.Approved, Vet Approved
ProcainamidePromazine may increase the QTc-prolonging activities of Procainamide.Approved
ProcaineThe risk or severity of adverse effects can be increased when Promazine is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of adverse effects can be increased when Procarbazine is combined with Promazine.Approved
ProchlorperazineThe metabolism of Prochlorperazine can be decreased when combined with Promazine.Approved, Vet Approved
ProgesteroneThe metabolism of Progesterone can be decreased when combined with Promazine.Approved, Vet Approved
ProguanilThe serum concentration of Promazine can be increased when it is combined with Proguanil.Approved
PromethazinePromethazine may increase the QTc-prolonging activities of Promazine.Approved
PropafenoneThe serum concentration of Promazine can be increased when it is combined with Propafenone.Approved
ProparacaineThe risk or severity of adverse effects can be increased when Promazine is combined with Proparacaine.Approved, Vet Approved
PropofolPropofol may increase the QTc-prolonging activities of Promazine.Approved, Investigational, Vet Approved
PropoxycaineThe risk or severity of adverse effects can be increased when Promazine is combined with Propoxycaine.Approved
PropranololThe metabolism of Propranolol can be decreased when combined with Promazine.Approved, Investigational
ProtriptylineProtriptyline may increase the QTc-prolonging activities of Promazine.Approved
PSD502The risk or severity of adverse effects can be increased when Promazine is combined with PSD502.Investigational
PseudoephedrineThe metabolism of Pseudoephedrine can be decreased when combined with Promazine.Approved
PyrimethamineThe serum concentration of Promazine can be increased when it is combined with Pyrimethamine.Approved, Vet Approved
PyronaridineThe serum concentration of Promazine can be increased when it is combined with Pyronaridine.Investigational
QuazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Quazepam.Approved, Illicit
QuetiapinePromazine may increase the QTc-prolonging activities of Quetiapine.Approved
QuinacrineThe serum concentration of Promazine can be increased when it is combined with Quinacrine.Approved
QuinagolideThe therapeutic efficacy of Quinagolide can be decreased when used in combination with Promazine.Approved
QuinidinePromazine may increase the QTc-prolonging activities of Quinidine.Approved
QuininePromazine may increase the QTc-prolonging activities of Quinine.Approved
RacloprideThe risk or severity of adverse effects can be increased when Promazine is combined with Raclopride.Investigational
RadicicolThe serum concentration of Promazine can be increased when it is combined with Radicicol.Experimental
RamelteonThe risk or severity of adverse effects can be increased when Promazine is combined with Ramelteon.Approved, Investigational
RanitidineThe metabolism of Ranitidine can be decreased when combined with Promazine.Approved
RanolazineRanolazine may increase the QTc-prolonging activities of Promazine.Approved, Investigational
RasagilineThe risk or severity of adverse effects can be increased when Rasagiline is combined with Promazine.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Remifentanil.Approved
RemoxiprideThe metabolism of Remoxipride can be decreased when combined with Promazine.Approved, Withdrawn
repinotanThe metabolism of repinotan can be decreased when combined with Promazine.Investigational
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Promazine.Approved
RifabutinThe metabolism of Promazine can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Promazine can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Promazine can be increased when combined with Rifapentine.Approved
RilpivirineRilpivirine may increase the QTc-prolonging activities of Promazine.Approved
RisperidoneRisperidone may increase the QTc-prolonging activities of Promazine.Approved, Investigational
RitanserinThe risk or severity of adverse effects can be increased when Promazine is combined with Ritanserin.Investigational
RitobegronPromazine may decrease the stimulatory activities of Ritobegron.Investigational
RitonavirThe metabolism of Promazine can be decreased when combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of adverse effects can be increased when Rizatriptan is combined with Promazine.Approved
RomifidineThe risk or severity of adverse effects can be increased when Promazine is combined with Romifidine.Vet Approved
RopinirolePromazine may increase the sedative activities of Ropinirole.Approved, Investigational
RopivacaineThe metabolism of Ropivacaine can be decreased when combined with Promazine.Approved
RotigotinePromazine may increase the sedative activities of Rotigotine.Approved
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Promazine.Approved
S-EthylisothioureaThe risk or severity of adverse effects can be increased when Promazine is combined with S-Ethylisothiourea.Experimental
Sage 547The risk or severity of adverse effects can be increased when Promazine is combined with Sage 547.Investigational
SalbutamolSalbutamol may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
SalmeterolSalmeterol may increase the QTc-prolonging activities of Promazine.Approved
SaquinavirPromazine may increase the QTc-prolonging activities of Saquinavir.Approved, Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Promazine is combined with Scopolamine.Approved
SecobarbitalThe metabolism of Promazine can be increased when combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Selegiline is combined with Promazine.Approved, Investigational, Vet Approved
SertindoleThe metabolism of Sertindole can be decreased when combined with Promazine.Approved, Withdrawn
SertralineSertraline may increase the QTc-prolonging activities of Promazine.Approved
SevofluraneSevoflurane may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
SildenafilThe metabolism of Promazine can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Promazine can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Promazine can be increased when it is combined with Simeprevir.Approved
SimvastatinThe metabolism of Simvastatin can be decreased when combined with Promazine.Approved
SinefunginThe serum concentration of Promazine can be increased when it is combined with Sinefungin.Experimental
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
SolifenacinSolifenacin may increase the QTc-prolonging activities of Promazine.Approved
SorafenibSorafenib may increase the QTc-prolonging activities of Promazine.Approved, Investigational
SotalolPromazine may increase the QTc-prolonging activities of Sotalol.Approved
SparteineThe metabolism of Sparteine can be decreased when combined with Promazine.Experimental
St. John's WortThe serum concentration of Promazine can be decreased when it is combined with St. John's Wort.Nutraceutical
StiripentolThe serum concentration of Promazine can be increased when it is combined with Stiripentol.Approved
SufentanilThe risk or severity of adverse effects can be increased when Promazine is combined with Sufentanil.Approved, Investigational
SulfadiazineThe metabolism of Promazine can be decreased when combined with Sulfadiazine.Approved, Vet Approved
SulfadoxineThe serum concentration of Promazine can be increased when it is combined with Sulfadoxine.Approved
SulfamethoxazoleSulfamethoxazole may increase the QTc-prolonging activities of Promazine.Approved
SulfametopyrazineThe serum concentration of Promazine can be increased when it is combined with Sulfametopyrazine.Approved, Withdrawn
SulfisoxazoleSulfisoxazole may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
SulpirideThe risk or severity of adverse effects can be increased when Promazine is combined with Sulpiride.Approved
SumatriptanThe risk or severity of adverse effects can be increased when Sumatriptan is combined with Promazine.Approved, Investigational
SunitinibSunitinib may increase the QTc-prolonging activities of Promazine.Approved, Investigational
SuvorexantPromazine may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved
tafenoquineThe serum concentration of Promazine can be increased when it is combined with tafenoquine.Investigational
TamoxifenThe serum concentration of the active metabolites of Tamoxifen can be reduced when Tamoxifen is used in combination with Promazine resulting in a loss in efficacy.Approved
TamsulosinThe metabolism of Tamsulosin can be decreased when combined with Promazine.Approved, Investigational
TandospironeThe risk or severity of adverse effects can be increased when Promazine is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of Promazine.Approved
TasimelteonThe risk or severity of adverse effects can be increased when Promazine is combined with Tasimelteon.Approved
Tedizolid PhosphateThe risk or severity of adverse effects can be increased when Tedizolid Phosphate is combined with Promazine.Approved
TegaserodThe metabolism of Tegaserod can be decreased when combined with Promazine.Investigational, Withdrawn
TelaprevirThe metabolism of Promazine can be decreased when combined with Telaprevir.Approved
TelavancinPromazine may increase the QTc-prolonging activities of Telavancin.Approved
TelithromycinPromazine may increase the QTc-prolonging activities of Telithromycin.Approved
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Promazine.Approved
TenofovirThe metabolism of Promazine can be decreased when combined with Tenofovir.Approved, Investigational
TerbutalineTerbutaline may increase the QTc-prolonging activities of Promazine.Approved
TerfenadineThe metabolism of Terfenadine can be decreased when combined with Promazine.Withdrawn
TeriflunomideThe serum concentration of Promazine can be decreased when it is combined with Teriflunomide.Approved
TesmilifeneThe metabolism of Tesmilifene can be decreased when combined with Promazine.Investigational
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Promazine.Approved
TetracaineThe risk or severity of adverse effects can be increased when Promazine is combined with Tetracaine.Approved, Vet Approved
TetrodotoxinThe risk or severity of adverse effects can be increased when Promazine is combined with Tetrodotoxin.Investigational
ThalidomidePromazine may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Promazine can be decreased when combined with Theophylline.Approved
ThiamylalThe risk or severity of adverse effects can be increased when Promazine is combined with Thiamylal.Approved, Vet Approved
ThiopentalThe risk or severity of adverse effects can be increased when Promazine is combined with Thiopental.Approved, Vet Approved
ThioridazinePromazine may increase the QTc-prolonging activities of Thioridazine.Approved
ThiothixeneThiothixene may increase the QTc-prolonging activities of Promazine.Approved
TiagabineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiagabine.Approved
TiaprideThe risk or severity of adverse effects can be increased when Promazine is combined with Tiapride.Investigational
TicagrelorThe metabolism of Promazine can be decreased when combined with Ticagrelor.Approved
TiclopidineThe metabolism of Promazine can be decreased when combined with Ticlopidine.Approved
TiletamineThe risk or severity of adverse effects can be increased when Promazine is combined with Tiletamine.Vet Approved
TimololThe metabolism of Timolol can be decreased when combined with Promazine.Approved
TiotropiumThe metabolism of Tiotropium can be decreased when combined with Promazine.Approved
TipranavirThe metabolism of Tipranavir can be decreased when combined with Promazine.Approved, Investigational
TizanidineTizanidine may increase the QTc-prolonging activities of Promazine.Approved
TocilizumabThe serum concentration of Promazine can be decreased when it is combined with Tocilizumab.Approved
TolbutamideThe metabolism of Promazine can be decreased when combined with Tolbutamide.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Promazine is combined with Tolcapone.Approved, Withdrawn
TolterodineTolterodine may increase the QTc-prolonging activities of Promazine.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Promazine is combined with Topiramate.Approved
ToremifenePromazine may increase the QTc-prolonging activities of Toremifene.Approved, Investigational
TrabectedinThe metabolism of Trabectedin can be decreased when combined with Promazine.Approved, Investigational
TramadolThe therapeutic efficacy of Tramadol can be decreased when used in combination with Promazine.Approved, Investigational
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Promazine is combined with Trans-2-Phenylcyclopropylamine.Experimental
TranylcypromineThe risk or severity of adverse effects can be increased when Promazine is combined with Tranylcypromine.Approved
TrazodoneTrazodone may increase the QTc-prolonging activities of Promazine.Approved, Investigational
TreprostinilTreprostinil may increase the QTc-prolonging activities of Promazine.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Promazine is combined with Triazolam.Approved
TrifluoperazineThe risk or severity of adverse effects can be increased when Promazine is combined with Trifluoperazine.Approved
TriflupromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Triflupromazine.Approved, Vet Approved
TrimethoprimThe serum concentration of Promazine can be increased when it is combined with Trimethoprim.Approved, Vet Approved
TrimipramineTrimipramine may increase the QTc-prolonging activities of Promazine.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Promazine is combined with Triprolidine.Approved
TriptorelinTriptorelin may increase the QTc-prolonging activities of Promazine.Approved, Vet Approved
Uc1010The risk or severity of adverse effects can be increased when Promazine is combined with Uc1010.Investigational
UmeclidiniumThe metabolism of Umeclidinium can be decreased when combined with Promazine.Approved
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Promazine.Approved, Investigational
ValsartanThe metabolism of Promazine can be decreased when combined with Valsartan.Approved, Investigational
VandetanibPromazine may increase the QTc-prolonging activities of Vandetanib.Approved
VardenafilVardenafil may increase the QTc-prolonging activities of Promazine.Approved
VemurafenibThe serum concentration of Promazine can be increased when it is combined with Vemurafenib.Approved
VenlafaxineVenlafaxine may increase the QTc-prolonging activities of Promazine.Approved
VerapamilThe metabolism of Promazine can be decreased when combined with Verapamil.Approved
VigabatrinThe risk or severity of adverse effects can be increased when Promazine is combined with Vigabatrin.Approved
VilanterolVilanterol may increase the QTc-prolonging activities of Promazine.Approved
VilazodoneThe metabolism of Vilazodone can be decreased when combined with Promazine.Approved
VinblastineThe metabolism of Vinblastine can be decreased when combined with Promazine.Approved
VinorelbineThe metabolism of Vinorelbine can be decreased when combined with Promazine.Approved, Investigational
VoriconazoleThe metabolism of Promazine can be decreased when combined with Voriconazole.Approved, Investigational
VorinostatVorinostat may increase the QTc-prolonging activities of Promazine.Approved, Investigational
VortioxetineThe metabolism of Vortioxetine can be decreased when combined with Promazine.Approved
XylazineThe risk or severity of adverse effects can be increased when Promazine is combined with Xylazine.Vet Approved
YohimbineThe metabolism of Yohimbine can be decreased when combined with Promazine.Approved, Vet Approved
ZafirlukastThe metabolism of Promazine can be decreased when combined with Zafirlukast.Approved, Investigational
ZalcitabineThe metabolism of Zalcitabine can be decreased when combined with Promazine.Approved
ZaleplonThe risk or severity of adverse effects can be increased when Promazine is combined with Zaleplon.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Promazine is combined with Ziconotide.Approved
ZimelidineThe risk or severity of adverse effects can be increased when Promazine is combined with Zimelidine.Withdrawn
ZiprasidonePromazine may increase the QTc-prolonging activities of Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Promazine is combined with Zolazepam.Vet Approved
ZolmitriptanThe risk or severity of adverse effects can be increased when Zolmitriptan is combined with Promazine.Approved, Investigational
ZolpidemPromazine may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Promazine is combined with Zonisamide.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when Promazine is combined with Zopiclone.Approved
ZotepineThe risk or severity of adverse effects can be increased when Promazine is combined with Zotepine.Approved
ZuclopenthixolPromazine may increase the QTc-prolonging activities of Zuclopenthixol.Approved, Investigational
Food InteractionsNot Available
References
Synthesis Reference

DrugSyn.org

US2519886
General References
  1. Cubala WJ, Jakuszkowiak-Wojten K, Burkiewicz A, Wronska A: Promazine in the treatment of delusional parasitosis. Psychiatr Danub. 2011 Jun;23(2):198-9. [PubMed:21685861 ]
External Links
ATC CodesN05AA03
AHFS Codes
  • 28:16.08.24
PDB EntriesNot Available
FDA labelNot Available
MSDSDownload (75.4 KB)
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9718
Blood Brain Barrier+0.987
Caco-2 permeable+0.8813
P-glycoprotein substrateSubstrate0.7933
P-glycoprotein inhibitor IInhibitor0.6857
P-glycoprotein inhibitor IIInhibitor0.6352
Renal organic cation transporterInhibitor0.7561
CYP450 2C9 substrateNon-substrate0.7526
CYP450 2D6 substrateSubstrate0.9334
CYP450 3A4 substrateSubstrate0.5578
CYP450 1A2 substrateInhibitor0.8935
CYP450 2C9 inhibitorNon-inhibitor0.9483
CYP450 2D6 inhibitorInhibitor0.9622
CYP450 2C19 inhibitorNon-inhibitor0.798
CYP450 3A4 inhibitorNon-inhibitor0.9166
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6784
Ames testNon AMES toxic0.9176
CarcinogenicityNon-carcinogens0.9545
BiodegradationNot ready biodegradable0.9921
Rat acute toxicity2.9416 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9662
hERG inhibition (predictor II)Inhibitor0.7828
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Wyeth ayerst laboratories
  • Watson laboratories inc
  • Baxter healthcare corp anesthesia critical care
  • Apothecon sub bristol myers squibb co
  • Apothecon inc div bristol myers squibb
  • Bristol myers squibb co
Packagers
Dosage forms
FormRouteStrength
LiquidIntramuscular; Intravenous50 mg
Prices
Unit descriptionCostUnit
Chlorpromazine 25 mg/ml amp8.04USD ml
Chlorpromazine 200 mg tablet1.05USD tablet
Chlorpromazine Hcl 25 mg/ml0.88USD ml
Chlorpromazine 100 mg tablet0.39USD tablet
Novo-Chlorpromazine 100 mg Tablet0.35USD tablet
Chlorpromazine 10 mg tablet0.32USD tablet
Chlorpromazine 50 mg tablet0.3USD tablet
Novo-Chlorpromazine 50 mg Tablet0.21USD tablet
Novo-Chlorpromazine 25 mg Tablet0.18USD tablet
Chlorpromazine 25 mg tablet0.17USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateLiquid
Experimental Properties
PropertyValueSource
melting point< 25 °CPhysProp
boiling point203-210 °C at 3.00E-01 mm HgPhysProp
water solubility14.2 mg/L (at 24 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP4.55HANSCH,C ET AL. (1995)
logS-4.3ADME Research, USCD
pKa9.36SANGSTER (1994)
Predicted Properties
PropertyValueSource
Water Solubility0.0207 mg/mLALOGPS
logP4.63ALOGPS
logP3.93ChemAxon
logS-4.1ALOGPS
pKa (Strongest Basic)9.2ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area6.48 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity88.95 m3·mol-1ChemAxon
Polarizability32.74 Å3ChemAxon
Number of Rings3ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Download (9.05 KB)
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-0a4i-9430000000-708a7cbef8d61ce76846View in MoNA
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenothiazines. These are polycyclic aromatic compounds containing a phenothiazine moiety, which is a linear tricyclic system that consists of a two benzene rings joined by a para-thiazine ring.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassBenzothiazines
Sub ClassPhenothiazines
Direct ParentPhenothiazines
Alternative Parents
Substituents
  • Phenothiazine
  • Alkyldiarylamine
  • Diarylthioether
  • Para-thiazine
  • Tertiary aliphatic amine
  • Tertiary amine
  • Azacycle
  • Thioether
  • Hydrocarbon derivative
  • Organonitrogen compound
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Potassium channel regulator activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which inhibit adenylyl cyclase.
Gene Name:
DRD2
Uniprot ID:
P14416
Molecular Weight:
50618.91 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Virus receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including mescaline, psilocybin, 1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modulates...
Gene Name:
HTR2A
Uniprot ID:
P28223
Molecular Weight:
52602.58 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Govitrapong P, Chagkutip J, Turakitwanakan W, Srikiatkhachorn A: Platelet 5-HT(2A) receptors in schizophrenic patients with and without neuroleptic treatment. Psychiatry Res. 2000 Sep 25;96(1):41-50. [PubMed:10980325 ]
  4. Govitrapong P, Mukda S, Turakitwanakan W, Dumrongphol H, Chindaduangratn C, Sanvarinda Y: Platelet serotonin transporter in schizophrenic patients with and without neuroleptic treatment. Neurochem Int. 2002 Oct;41(4):209-16. [PubMed:12106771 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Serotonin receptor activity
Specific Function:
G-protein coupled receptor for 5-hydroxytryptamine (serotonin). Also functions as a receptor for various drugs and psychoactive substances, including ergot alkaloid derivatives, 1-2,5,-dimethoxy-4-iodophenyl-2-aminopropane (DOI) and lysergic acid diethylamide (LSD). Ligand binding causes a conformation change that triggers signaling via guanine nucleotide-binding proteins (G proteins) and modul...
Gene Name:
HTR2C
Uniprot ID:
P28335
Molecular Weight:
51820.705 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled amine receptor activity
Specific Function:
Dopamine receptor whose activity is mediated by G proteins which activate adenylyl cyclase.
Gene Name:
DRD1
Uniprot ID:
P21728
Molecular Weight:
49292.765 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Sh3 domain binding
Specific Function:
Dopamine receptor responsible for neuronal signaling in the mesolimbic system of the brain, an area of the brain that regulates emotion and complex behavior. Its activity is mediated by G proteins which inhibit adenylyl cyclase. Modulates the circadian rhythm of contrast sensitivity by regulating the rhythmic expression of NPAS2 in the retinal ganglion cells (By similarity).
Gene Name:
DRD4
Uniprot ID:
P21917
Molecular Weight:
48359.86 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Guanyl-nucleotide exchange factor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is inhibition of adenylate cyclase.
Gene Name:
CHRM4
Uniprot ID:
P08173
Molecular Weight:
53048.65 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
G-protein coupled acetylcholine receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is adenylate cyclase inhibition. Signaling promotes phospholipase C activity, leading to the release of inositol trisphosphate (IP3); this then trigge...
Gene Name:
CHRM2
Uniprot ID:
P08172
Molecular Weight:
51714.605 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Receptor activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM3
Uniprot ID:
P20309
Molecular Weight:
66127.445 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM1
Uniprot ID:
P11229
Molecular Weight:
51420.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Phosphatidylinositol phospholipase c activity
Specific Function:
The muscarinic acetylcholine receptor mediates various cellular responses, including inhibition of adenylate cyclase, breakdown of phosphoinositides and modulation of potassium channels through the action of G proteins. Primary transducing effect is Pi turnover.
Gene Name:
CHRM5
Uniprot ID:
P08912
Molecular Weight:
60073.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Histamine receptor activity
Specific Function:
In peripheral tissues, the H1 subclass of histamine receptors mediates the contraction of smooth muscles, increase in capillary permeability due to contraction of terminal venules, and catecholamine release from adrenal medulla, as well as mediating neurotransmission in the central nervous system.
Gene Name:
HRH1
Uniprot ID:
P35367
Molecular Weight:
55783.61 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Hals PA, Hall H, Dahl SG: Muscarinic cholinergic and histamine H1 receptor binding of phenothiazine drug metabolites. Life Sci. 1988;43(5):405-12. [PubMed:2899826 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Molecular Weight:
58293.76 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
  2. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Molecular Weight:
55627.365 Da
References
  1. Zhou SF, Zhou ZW, Yang LP, Cai JP: Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675. Epub 2009 Sep 1. [PubMed:19515014 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23